Benjamin J. Hindson Sells 2,361 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

10x Genomics, Inc. (NASDAQ:TXGGet Rating) insider Benjamin J. Hindson sold 2,361 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the transaction, the insider now directly owns 217,713 shares in the company, valued at approximately $7,417,481.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

10x Genomics Stock Up 3.6 %

Shares of TXG traded up $1.28 during mid-day trading on Thursday, hitting $36.44. 711,354 shares of the company’s stock were exchanged, compared to its average volume of 1,642,890. The firm has a fifty day moving average of $30.63 and a two-hundred day moving average of $38.09. 10x Genomics, Inc. has a twelve month low of $23.81 and a twelve month high of $157.74. The stock has a market cap of $4.17 billion, a price-to-earnings ratio of -24.62 and a beta of 1.58.

10x Genomics (NASDAQ:TXGGet Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09. The business had revenue of $131.10 million during the quarter, compared to the consensus estimate of $129.13 million. 10x Genomics had a negative net margin of 33.20% and a negative return on equity of 21.01%. 10x Genomics’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.15) EPS. On average, equities analysts predict that 10x Genomics, Inc. will post -1.61 earnings per share for the current year.

Institutional Trading of 10x Genomics

Several large investors have recently modified their holdings of TXG. Wipfli Financial Advisors LLC bought a new stake in 10x Genomics in the 3rd quarter valued at $26,000. First Horizon Advisors Inc. increased its position in shares of 10x Genomics by 14,780.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 744 shares of the company’s stock worth $33,000 after purchasing an additional 739 shares in the last quarter. Atlas Capital Advisors LLC increased its position in shares of 10x Genomics by 45.5% during the 3rd quarter. Atlas Capital Advisors LLC now owns 1,360 shares of the company’s stock worth $39,000 after purchasing an additional 425 shares in the last quarter. Standard Family Office LLC acquired a new stake in shares of 10x Genomics during the 1st quarter worth about $59,000. Finally, Rockefeller Capital Management L.P. increased its position in 10x Genomics by 95.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,875 shares of the company’s stock valued at $81,000 after acquiring an additional 1,402 shares in the last quarter. 74.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

TXG has been the subject of a number of recent analyst reports. Cowen raised their price objective on shares of 10x Genomics from $50.00 to $55.00 in a research report on Tuesday, August 9th. The Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $35.00 to $25.00 and set a “sell” rating for the company in a research note on Thursday, October 13th. Cowen boosted their price objective on shares of 10x Genomics to $55.00 in a research note on Monday, August 15th. Citigroup lowered their price objective on shares of 10x Genomics from $100.00 to $65.00 in a research note on Tuesday, August 9th. Finally, JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $65.00 to $55.00 in a report on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $51.13.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Read More

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.